Table III.
Clinicopathological characteristics associated with a CD44+/CD24− phenotype in invasive breast cancer tissue samples.
| Clinicopathological characteristic | CD44+/CD24− positive patients (%) | P-value |
|---|---|---|
| Menopausal state | 0.057 | |
| Pre-menopausal | 5.9 | |
| Post-menopausal | 29.6 | |
| T stage | 0.366 | |
| ≤T1 | 25.9 | |
| ≥T2 | 15.0 | |
| Node metastasis | 0.038 | |
| Negative | 31.0 | |
| Positive | 5.6 | |
| Histologic grade | 0.092 | |
| 1 | 50.0 | |
| 2 | 16.7 | |
| 3 | 14.8 | |
| Lymphovascular invasion | 0.366 | |
| Negative | 25.9 | |
| Positive | 15.0 | |
| ER expression status | 0.536 | |
| Negative | 26.7 | |
| Positive | 18.8 | |
| PR expression status | 0.103 | |
| Negative | 40.0 | |
| Positive | 16.2 | |
| HER2 overexpression status | 0.347 | |
| Negative | 29.2 | |
| Positive | 16.7 | |
| Bcl-2 expression status | 0.778 | |
| Negative | 25.0 | |
| Positive | 20.5 | |
| p53 expression status | 0.609 | |
| Negative | 28.6 | |
| Positive | 20.0 | |
| Ki-67 index | 0.322 | |
| <10% | 50.0 | |
| ≥10% | 20.5 | |
| EGFR expression status | 0.579 | |
| Negative | 19.4 | |
| Positive | 27.3 | |
| Molecular subtype | 0.042 | |
| Luminal A | 44.4 | |
| Luminal B | 8.7 | |
| HER2 | 33.3 | |
| Basal-like | 66.7 | |
| Intratumoral inflammation | 0.032 | |
| Negative | 50.0 | |
| Positive | 14.3 | |
| Peritumoral inflammation | 0.156 | |
| Negative | 50.0 | |
| Positive | 18.8 |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; Ki-67, proliferation marker protein Ki-67; Bcl-2, apoptosis regulator Bcl-2; p53, cellular tumor antigen p53.